IPP Bureau
European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors
By IPP Bureau - November 21, 2024
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Briefs: Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals
By IPP Bureau - November 20, 2024
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules
By IPP Bureau - November 20, 2024
The product will be manufactured at Lupin’s Somerset facility in the US
Lupin launches Bumetanide Injection USP in US
By IPP Bureau - November 20, 2024
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Emcure Pharma’s SAKHI - Diabetes awareness program makes to Asia Book of Records
By IPP Bureau - November 20, 2024
Indegene announces new Center in Hyderabad
By IPP Bureau - November 20, 2024
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
CPHI India reports surge in exhibitor numbers
By IPP Bureau - November 20, 2024
Modernization and supply chain diversity drive new growth
DKSH and Abcam join forces to advance life science research in Vietnam
By IPP Bureau - November 19, 2024
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide
By IPP Bureau - November 19, 2024
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
By IPP Bureau - November 19, 2024
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Sanofi invests €40 million to strengthen antibody bioproduction in France
By IPP Bureau - November 19, 2024
Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
By IPP Bureau - November 19, 2024
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
.jpg "Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness")
Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness
By IPP Bureau - November 17, 2024
Emcure and Dhoni, through a video, urge everyone to be aware about symptoms of stroke and educate at least one person for identification of stroke and spread its awareness
Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
By IPP Bureau - November 16, 2024
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Zota Health Care Q2 FY25 revenue up 48.6%
By IPP Bureau - November 16, 2024
Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%
